In the Presidential Session of the 2026 European Hematology Association (EHA) Annual Meeting, Prof. Lars Bullinger from Charité – Universitätsmedizin Berlin delivered a keynote speech titled "From gene profiles to therapy profiles - a quarter century of molecular hematology." Combining his personal research experience with global major scientific breakthroughs, Prof. Bullinger provided a profound analysis of the evolutionary path of hematologic malignancies, represented by Acute Myeloid Leukemia (AML), from morphological classification to molecular precision diagnosis and treatment.

In the treatment of acute myeloid leukemia (AML), the FLT3 mutation is one of the most common genetic abnormalities (accounting for approximately 30%), and the evolution of its treatment strategies has always been a focus of clinical attention. Although the first-generation FLT3 inhibitor midostaurin and the second-generation inhibitor quizartinib have been approved for first-line treatment, direct head-to-head data for the second-generation inhibitor gilteritinib versus midostaurin in the context of first-line intensive chemotherapy were previously a blank.

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Martin Schrappe, on behalf of the AIEOP-BFM consortium, announced the latest analysis data from the Phase III randomized controlled clinical trial AIEOP-BFM ALL 2017. This study aimed to explore the clinical benefits of using the bispecific antibody Blinatumomab to completely replace two cycles of high-intensity toxic chemotherapy in newly diagnosed pediatric and adolescent patients with high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL). The results showed that this strategy not only significantly improved the event-free survival (EFS) rate of patients but also substantially reduced treatment-related toxicity and transplant-related mortality.

Although progress has been made in the treatment of Acute Myeloid Leukemia (AML) over the past few decades, clinical options remain very limited for patients with relapsed/refractory (R/R) disease. Chimeric Antigen Receptor T-cell (CAR-T) therapy has achieved revolutionary breakthroughs in B-cell malignancies; however, its application in the field of AML has faced significant challenges due to limitations in target selection, patient T-cell quality, and potential toxicities (such as long-term bone marrow suppression).

In the recent European Hematology Association (EHA) Annual Meeting, Professor Mats Jerkeman from Lund University, Sweden, provided an in-depth interpretation of the diagnosis and latest treatment guidelines for Mantle Cell Lymphoma (MCL). With the release of results from several large-scale clinical trials (such as TRIANGLE, ECHO, SHINE, etc.), the treatment landscape for MCL is undergoing a transformation from traditional chemo-immunotherapy to precision targeted therapies centered on BTK inhibitors (BTKi).

At a recent international academic conference, Professor Matthew Davids from the Dana-Farber Cancer Institute in the United States announced the interim analysis results of the Phase 3 randomized controlled clinical trial, BRUIN CLL-322. This study aimed to evaluate the efficacy and safety of fixed-duration pirtobrutinib plus venetoclax and rituximab (PVR regimen) versus venetoclax plus rituximab (VR regimen) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Meletios Dimopoulos from the National and Kapodistrian University of Athens was invited to deliver a presentation titled "Mezigdomide, Carfilzomib, and Dexamethasone (MeziKd) vs Carfilzomib and Dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 SUCCESSOR-2 Trial."

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Niels van de Donk from the Amsterdam University Medical Center (Amsterdam UMC), representing the EMN30 study group, announced the updated safety run-in (SRI) results of the EMN30/MAJESTEC-4 study. This study aims to evaluate the safety and preliminary efficacy of the BCMA×CD3 bispecific antibody Teclistamab (Tec), either as monotherapy or in combination with Lenalidomide (Len), as maintenance therapy for patients with newly diagnosed multiple myeloma (NDMM) following autologous stem cell transplantation (ASCT).

At the EHA 2026 conference, Professor Omar Nadeem from the Dana-Farber Cancer Institute (USA) announced the latest results of the Phase II ImmunoPRISM trial. This study compared the BCMA×CD3 bispecific antibody Teclistamab with the standard regimen of lenalidomide + dexamethasone (Rd) in patients with high-risk smoldering multiple myeloma (HRSMM), providing heavy evidence for early precision intervention in this field.

In June 2026, the world-renowned European Hematology Association (EHA) Annual Congress grandly opened in Stockholm, Sweden. As one of the largest and most influential academic events in the global field of hematology, this year's EHA Congress not only brought together top-tier academic research results but also defined the development direction for global hematology diagnosis and treatment over the next five to ten years through the release of a series of strategic blueprints. The opening ceremony covered strategic addresses from the Board of Directors, research grant awards, DEI (Diversity, Equity, and Inclusion) and Education & Mentoring awards, as well as a highly prestigious Lifetime Achievement Award lecture. Experts showcased the rapid transformation of hematology in the era of precision medicine from a comprehensive perspective, ranging from macro-level industry policies to micro-level molecular biological mechanisms.